Experimental research on the depressant effect of aspirin on Ishikawa adenocarcinoma endometrium cell growth.
OBJECTIVE
: To investigate the effect of aspirin on human Ishikawa adenocarcinoma endometrium cell proliferation and apoptosis and its related mechanism through in vitro experiments.


METHODS
: The effects on Ishikawa adenocarcinoma endometrium cell proliferation and cell cycle of aspirin at different intervals and concentrations were determined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method and flow cytometry; cell morphous change after the effect of aspirin was observed with transmission electron microscope; and the effect of aspirin on B-cell lymphoma/leukemia-x, long (Bcl-xl) proteinum expression was determined with Western blot.


RESULTS
: Aspirin had a significant depressant effect on human Ishikawa adenocarcinoma endometrium cell proliferation, and the effect showed time and dose dependence (P < 0.05). Aspirin-induced cell blockage at G1 phase, elevated cell apoptosis rate, and its effect were related with its concentration (P < 0.05). After treatment, cell volume was reduced, chromatin was seen concentrated and aggregated around the edge of nuclear membrane, and apoptotic body was formed. Aspirin decreased Bcl-xl proteinum expression, and the effect was related with its concentration (P < 0.05).


CONCLUSIONS
: Aspirin has a distinct depressant effect on human Ishikawa adenocarcinoma endometrium cell growth, and its effect may be realized by lowering Bcl-xl proteinum expression.
Xiaoxin
Ma
M
Department of Gynaecology and Obstetrics, Shengjing Hospital of China Medical University, Shenyang, China. maxiaoxin666@yahoo.com.cn
Yingnan
Jin
J
Yanxia
Li
L
Shu
Li
L
Yuanqi
He
H
Hongwei
Lv
L
D000230:Adenocarcinoma / Q000378:metabolism / Q000473:pathology*; D017209:Apoptosis / Q000187:drug effects; D001241:Aspirin / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D016889:Endometrial Neoplasms / Q000378:metabolism / Q000473:pathology*; D005260:Female; D006801:Humans; D013997:Time Factors; D051020:bcl-X Protein / Q000378:metabolism
C494811:BCL2L1 protein, human; D051020:bcl-X Protein; D001241:Aspirin